[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Watanabe Y, Endou A, Ooi S, Matsushima E, Shimisu Y, Nakashima K: Extraosseous epidural IgD myeloma presenting with compression myelopathy. Psychiatry Clin Neurosci; 2000 Dec;54(6):665-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous epidural IgD myeloma presenting with compression myelopathy.
  • Immunoelectrophoresis revealed the presence of immunoglobulin D (IgD)-lambda M protein.
  • Chemotherapy markedly improved both the haematologic aspect and tumor size, but not the motor deficit.
  • In IgD myeloma, extraosseous spreads occur frequently, but extraosseous epidural tumors causing compression myelopathy are relatively rare.
  • [MeSH-major] Immunoglobulin D. Multiple Myeloma / pathology. Spinal Cord Compression / pathology

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11145465.001).
  • [ISSN] 1323-1316
  • [Journal-full-title] Psychiatry and clinical neurosciences
  • [ISO-abbreviation] Psychiatry Clin. Neurosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


2. Takemori N, Kondo K, Kawamura T, Imai K, Sakurai H, Sato T: Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment. Am J Hematol; 2001 Jan;66(1):62-3
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
  • IgD myeloma is an infrequent type of multiple myeloma and is characterized by an aggressive clinical behavior and a short survival time.
  • No satisfactory treatments have thus far been established.
  • Recently we treated a patient with IgD(lambda)-type myeloma with glucocorticoids, and succeeded in achieving a complete remission.
  • This case seems to indicate a usefulness of glucocorticoid monotherapy for treating IgD myeloma.
  • [MeSH-major] Glucocorticoids / therapeutic use. Immunoglobulin D / blood. Immunoglobulin lambda-Chains / blood. Multiple Myeloma / drug therapy. Myeloma Proteins / analysis. Prednisolone / therapeutic use
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Interferons / therapeutic use. Melphalan / administration & dosage. Methylprednisolone / administration & dosage. Middle Aged. Nitrosourea Compounds / administration & dosage. Remission Induction. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426497.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunoglobulin D; 0 / Immunoglobulin lambda-Chains; 0 / Myeloma Proteins; 0 / Nitrosourea Compounds; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9008-11-1 / Interferons; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; RYH2T97J77 / ranimustine; X4W7ZR7023 / Methylprednisolone; C-VAMP protocol
  •  go-up   go-down


3. Sharma M, Qureshi SR, Champlin RE, Popat U, Giralt S, Qazilbash MH: The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes. Am J Hematol; 2010 Jul;85(7):502-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes.
  • IgD myeloma is a rare subtype of myeloma that is associated with an aggressive course, resistance to chemotherapy, and a poor outcome.
  • We identified 17 patients with IgD myeloma, who received a hematopoietic stem cell transplantation (HCT) at our institution between August 1988 and June 2008.
  • These results were comparable with patients receiving autologous HCT for other Ig subtypes of myeloma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Immunoglobulin D. Multiple Myeloma / therapy
  • [MeSH-minor] Adult. Female. Humans. Immunoglobulin Isotypes. Male. Middle Aged. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • (PMID = 20575022.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin Isotypes
  •  go-up   go-down


Advertisement
4. Chong YP, Kim S, Ko OB, Koo JE, Lee D, Park SH, Park SJ, Lee D, Kim SW, Suh C: Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience. J Korean Med Sci; 2008 Oct;23(5):819-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcomes for IgD multiple myeloma patients following high-dose melphalan and autologous stem cell transplantation: a single center experience.
  • Immunoglobulin (Ig) D multiple myeloma (MM) accounts for 2% of all MM cases and has been reported to be associated with poor prognosis compared with other MM subtypes.
  • The aim of the present study was to compare the effects of high-dose melphalan treatment and autologous stem cell transplantation (ASCT) on the survival of patients with IgD MM and patients with other MM subtypes.
  • High-dose melphalan (total 200 mg/m2) was used as high-dose chemotherapy.
  • The study population was divided into two groups based on MM subtype: those with IgD MM; and those with other MM subtypes.
  • A total of 8 patients with IgD MM were identified, accounting for about 10% of the study population.
  • In the IgD MM group, median eventfree survival (EFS) and OS were 6.9 and 12 months, respectively.
  • Multivariate analysis of all patients identified IgD subtype (p=0.002) and Southwest Oncology Group (SWOG) stage 2 or greater at the time of ASCT (p=0.01) as adverse prognostic factors for survival.
  • In this small study at a single center in Korea, patients with IgD MM had poorer outcomes after ASCT than did patients with other MM subtypes.
  • [MeSH-major] Immunoglobulin D / chemistry. Melphalan / pharmacology. Multiple Myeloma / drug therapy. Multiple Myeloma / immunology. Myeloablative Agonists / pharmacology. Stem Cell Transplantation / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Intern Med. 1975 Jan;135(1):87-93 [1111472.001]
  • [Cites] Clin Lab Haematol. 2006 Jun;28(3):189-97 [16706936.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2398-404 [7964956.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] Bone Marrow Transplant. 2001 Jul;28(1):29-37 [11498741.001]
  • [Cites] Clin Lab. 2002;48(11-12):617-22 [12465746.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):163-70 [12621476.001]
  • [Cites] Lancet Oncol. 2003 May;4(5):293-304 [12732167.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Leuk Lymphoma. 2003 May;44(5):749-58 [12802910.001]
  • [Cites] Br J Haematol. 2003 Aug;122(3):441-50 [12877671.001]
  • [Cites] Bone Marrow Transplant. 2003 Dec;32(12):1135-43 [14647267.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2495-502 [14695409.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] J Exp Med. 1965 Jan 1;121:171-84 [14253482.001]
  • [Cites] Transfusion. 2004 Dec;44(12):1762-8 [15584992.001]
  • [Cites] Ann Hematol. 2005 Feb;84(2):115-7 [15503021.001]
  • [Cites] Bone Marrow Transplant. 2005 Jan;35(2):159-64 [15543200.001]
  • [Cites] J Clin Oncol. 2005 May 20;23(15):3412-20 [15809451.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1133-40 [15834435.001]
  • [Cites] Bone Marrow Transplant. 2006 Apr;37(8):731-7 [16501593.001]
  • [Cites] Cancer. 2006 May 15;106(10):2171-80 [16598756.001]
  • [Cites] Scand J Haematol. 1984 Nov;33(5):471-5 [6515330.001]
  • [CommentIn] Acta Haematol. 2016;136(3):140-6 [27409804.001]
  • (PMID = 18955788.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Myeloablative Agonists; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC2580008
  •  go-up   go-down


5. Duvic C, Sarret D, De Revel T, Hérody M, Didelot F, Labaye J, Nédélec G: [IgD myeloma manifesting as acute renal insufficiency]. Rev Med Interne; 2000 Sep;21(9):799-803
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IgD myeloma manifesting as acute renal insufficiency].
  • [Transliterated title] Myélome à IgD révélé par une insuffisance rénale aiguë.
  • INTRODUCTION: IgD myeloma is a rare disease, comprising only 1-2% of all cases of myeloma.
  • EXEGESIS: A 71-year-old woman was admitted with acute renal failure, hypercalcemia and IgD lambda multiple myeloma.
  • Six monthly cures of chemotherapy of induction according to the protocol VAD (vincristine, doxorubicin and dexamethasone) allowed to achieve moderate chronic renal failure (serum creatinine = 120 mumol/L).
  • Sixteen months later, the patient developed an abdominal mass due to an IgD plasmocytoma in spite of treatment with interferon alpha and dexamethasone.
  • Chemotherapy with melphalan and dexamethasone allowed to the disappearance of plasmocytoma and remission.
  • The death occurred 36 months after the diagnosis.
  • CONCLUSION: This observation allows to display the particularities of IgD myeloma: remarkable preponderance of lambda-type light chains, small or no visible monoclonal spike on serum electrophoresis, frequent extraosseous spread of tumor, renal failure and presence of osteolytic lesions.
  • Over the last years, management and prediction of the survival time of IgD myeloma patients have improved.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11039177.001).
  • [ISSN] 0248-8663
  • [Journal-full-title] La Revue de medecine interne
  • [ISO-abbreviation] Rev Med Interne
  • [Language] FRE
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin D; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; AYI8EX34EU / Creatinine
  • [Number-of-references] 15
  •  go-up   go-down


6. Colombo I, Fruguglietti ME, Napoli L, Sciacco M, Tagliaferri E, Della Volpe A, Crugnola V, Bresolin N, Moggio M, Prelle A: IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis. Neurol Res Int; 2010;2010:808474
Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD Multiple Myeloma Paraproteinemia as a Cause of Myositis.
  • A 48-years old man was diagnosed an IgD-k multiple myeloma (MM) at age 38 years for which he successfully underwent chemotherapy and bone marrow transplant.
  • He then developed a graft-versus-host disease (GVHD) whose manifestations included, three years later, a polymyositis, diagnosed at muscle biopsy and successfully treated with steroids.
  • Few months after polymyositis remission, myeloma relapsed and the patient was treated with thalidomide for six years with good remission.
  • Direct immunofluorescence for IgD showed diffuse positivity along the sarcolemmal in both muscle biopsies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21188228.001).
  • [ISSN] 2090-1860
  • [Journal-full-title] Neurology research international
  • [ISO-abbreviation] Neurol Res Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3003993
  •  go-up   go-down


7. Reece DE, Vesole DH, Shrestha S, Zhang MJ, Pérez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN: Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):458-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with IgD and IgM multiple myeloma undergoing autologous hematopoietic stem cell transplantation: a retrospective CIBMTR study.
  • INTRODUCTION: Immunoglobulin D (IgD) and IgM multiple myeloma represent uncommon immunoglobulin isotypes, accounting for 2% and 0.5% of cases, respectively.
  • Limited information is available regarding the prognosis of these isotypes, but they have been considered to have a more aggressive course than the more common immunoglobulin G (IgG) and IgA isotypes.
  • PATIENTS AND METHODS: Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified 36 patients with IgD and 11 patients with IgM myeloma among 3578 myeloma patients who received intensive therapy and auto-HCT over a 10-year period.
  • RESULTS: The progression-free and overall survival probabilities at 3 years were 38% (95% CI, 21%-56%) and 69% (95% CI, 51%-84%) for IgD myeloma, and 47% (95% CI, 17%-78%) and 68% (95% CI, 36%-93%), respectively, for IgM disease.
  • Although formal statistical analysis was limited by the small sample size, these results were comparable to those for IgG and IgA patients autografted during the same time period.
  • Transplantation-related mortality and disease relapse/progression of myeloma were also similar for all isotypes.
  • CONCLUSION: This analysis demonstrates comparable outcomes in all immunoglobulin isotypes.
  • Therefore, auto-HCT should be offered to eligible patients with IgD and IgM myeloma.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 1999 Dec;13(6):1259-72 [10626149.001]
  • [Cites] J Korean Med Sci. 2008 Oct;23(5):819-24 [18955788.001]
  • [Cites] Br J Haematol. 2009 Apr;145(1):134-7 [19120351.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1570-1 [12393502.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Arch Intern Med. 1975 Jan;135(1):87-93 [1111472.001]
  • [Cites] Rev Med Interne. 1990 Jan-Feb;11(1):13-8 [2109345.001]
  • [Cites] J Clin Oncol. 1994 Nov;12(11):2398-404 [7964956.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Stat Med. 1999 Mar 30;18(6):695-706 [10204198.001]
  • [Cites] Ann Hematol. 2005 Feb;84(2):115-7 [15503021.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 15;162(2):183-4 [16213370.001]
  • [Cites] Ann Hematol. 2002 Mar;81(3):136-9 [11904738.001]
  • [Cites] Leuk Lymphoma. 2006 Aug;47(8):1565-9 [16966268.001]
  • [Cites] Bone Marrow Transplant. 2008 Jan;41(1):51-4 [17934529.001]
  • [Cites] Br J Haematol. 2008 Mar;140(5):547-51 [18275432.001]
  • (PMID = 21156462.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / U01 HL069294; United States / NCI NIH HHS / CA / U24 CA076518; United States / NHLBI NIH HHS / HL / 5U01HL069294; United States / NCI NIH HHS / CA / U24-CA76518
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin M
  • [Other-IDs] NLM/ NIHMS377845; NLM/ PMC3370942
  •  go-up   go-down


8. Kim YM, Lee KK, Oh HS, Park SK, Won JH, Hong DS, Park HS, Park JS, Lee DW: Myelomatous effusion with poor response to chemotherapy. J Korean Med Sci; 2000 Apr;15(2):243-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myelomatous effusion with poor response to chemotherapy.
  • While pleural effusion in multiple myeloma is relatively infrequent, myelomatous pleural effusion is extremely rare.
  • We experienced a 61-year-old woman with IgD-lambda multiple myeloma and pleural effusion.
  • The diagnosis was made originally by pleural biopsy, pleural fluid cytology and immunoelectropheresis of pleural fluid.
  • Transient improvement of the pleural effusion was observed after administration of combination chemotherapy of vincristine, melphalan, cyclophosphamide, prednisone (VMCP)/vincristine, cyclophosphamide, adriamycin, prednisone (VCAP).
  • Two months later, myelomatous pleural effusion recurred and no response to salvage therapy was observed.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Pleural Effusion / etiology
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Female. Humans. Melphalan / administration & dosage. Middle Aged. Plasma Cells / pathology. Prednisone / administration & dosage. Tomography, X-Ray Computed. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10803706.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] KOREA (SOUTH)
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone; VMCP protocol
  • [Other-IDs] NLM/ PMC3054621
  •  go-up   go-down


9. Sinclair D: IgD myeloma: clinical, biological and laboratory features. Clin Lab; 2002;48(11-12):617-22
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD myeloma: clinical, biological and laboratory features.
  • The study of IgD myeloma remains a challenging field.
  • In terms of the initial detection of the IgD paraprotein, great care must be exercised in the interpretation of electrophoresis patterns and immunoglobulin profiles.
  • Laboratory staff have a very important role to play in this, as it is likely that many IgD myeloma cases are uncovered following the involvement of laboratory staff.
  • They must help to ensure that suggestive electrophoresis and immunoglobulin levels are properly investigated and that Bence Jones myeloma is not diagnosed without excluding the presence of an IgD paraprotein.
  • In clinical terms, IgD myeloma remains a rare but aggressive tumour affecting younger people and with presenting features that include most of those common to all myeloma cases.
  • There are now increasing numbers of case reports describing patients with associative symptoms and only time will tell whether these relationships are predictive or useful in nature.
  • There do not appear to be any treatment regimes that are specifically tailored for IgD myeloma and the response to chemotherapy does not seem to differ from other forms of the disease.
  • The progress being made in the treatment of myeloma as a whole, is bound to have a positive impact on the treatment of IgD myeloma.
  • [MeSH-major] Immunoglobulin D. Multiple Myeloma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12465746.001).
  • [ISSN] 1433-6510
  • [Journal-full-title] Clinical laboratory
  • [ISO-abbreviation] Clin. Lab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Paraproteins; 9006-99-9 / Bence Jones Protein
  • [Number-of-references] 63
  •  go-up   go-down


10. Bemelmans RH, van Toorn DW, van Leeuwen L, Schaar CG: Long-term complete remission in IgD-myeloma. Eur J Haematol; 2006 Apr;76(4):339-41
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term complete remission in IgD-myeloma.
  • Long-term complete remission in IgD multiple myeloma (MM) is rare.
  • This case report describes a patient with a stage IIIB IgD-MM, who was treated with conventional melphalan and prednisone chemotherapy.
  • The monoclonal protein disappeared after four cycles and therapy was discontinued after 14 cycles.
  • In addition a concise review on IgD-MM is given.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Immunoglobulin D / blood. Melphalan / administration & dosage. Multiple Myeloma / blood. Multiple Myeloma / drug therapy. Prednisone / administration & dosage

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519706.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin D; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Ochiai N, Shimazaki C, Okano A, Hatsuse M, Takahashi R, Hirai H, Ashihara E, Inaba T, Fujita N, Nakagawa M: Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma. Leuk Lymphoma; 2002 Mar;43(3):641-3
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal relapse after double peripheral blood stem cell transplantation in IgD myeloma.
  • A 54-year-old man diagnosed with IgD myeloma (stage IIIA) in complete remission (CR) received peripheral blood stem cell transplantation (PBSCT) twice with an interval of 4 months using high-dose melphalan 200mg/m2.
  • A lumbar puncture revealed myeloma cells in the cerebrospinal fluid (CSF).
  • The patient did not respond to any salvage chemotherapy and died of sepsis 27 months after the initial diagnosis.
  • The findings in this patient suggest that another treatment modality including prophylactic intrathecal injection of an anti-cancer drug as well as allogeneic cell therapy is probably necessary in patients with high-risk IgD myeloma.
  • [MeSH-major] Meningeal Neoplasms / etiology. Multiple Myeloma / pathology. Multiple Myeloma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Fatal Outcome. Humans. Immunoglobulin D. Male. Middle Aged. Recurrence

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002772.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


12. Wechalekar A, Amato D, Chen C, Keith Stewart A, Reece D: IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation. Ann Hematol; 2005 Feb;84(2):115-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
  • IgD myeloma accounts for 2% of myeloma subtypes and has higher incidence of complications and a poorer outcome.
  • The characteristics and outcomes of 25 patients with IgD myeloma (2.6% of all myeloma patients), including 11 patients treated with autologous stem cell transplantation (ASCT) are reported.
  • The presenting features were not unique for myeloma, but it appears that the commonest presenting symptom was bone pain in 20 (80%) patients.
  • A total of 11 patients were treated with ASCT, while 14 patients had chemotherapy alone.
  • The response to treatment was: in the ASCT group 2 had a complete response (CR) and 9 had a good partial response (PR), while in the chemotherapy group 6 had a good PR with no CRs.
  • The median PFS after chemotherapy was 1.23 years (95% CI 1.02-1.44).
  • The mean OS transplantation was 5.09 years compared with 2.03 years for those treated with chemotherapy alone.
  • This small series appears to suggest that outcome for IgD myeloma remains poor with chemotherapy and appears to be superior with ASCT, and larger studies are needed to confirm these findings.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation / mortality. Immunoglobulin D. Multiple Myeloma / mortality. Multiple Myeloma / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Data Collection. Female. Humans. Male. Middle Aged. Remission Induction. Retrospective Studies. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15503021.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


13. Kawauchi K, Ogasawara T, Yasuyama M, Ohkawa S, Aiba M: [Testicular involvement in IgD multiple myeloma]. Rinsho Ketsueki; 2001 Nov;42(11):1128-33
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Testicular involvement in IgD multiple myeloma].
  • He was diagnosed as having multiple myeloma due to the presence of IgD lambda monoclonal gammopathy and diffuse infiltration of plasma cells in the bone marrow.
  • The patient achieved a partial response to DMVM-IFN-alpha combination therapy.
  • His condition worsened in December 1998, but was ameliorated by VAD therapy.
  • The normal testicular cells had been entirely displaced by myeloma cells comprising typical plasma cells and large lymphoid cells.
  • Pleural, mediastinal, spinal, and right testicular involvement with myeloma subsequently developed.
  • Despite attempts to treat the patient with more than one type of combination therapy, his condition worsened progressively, and he died in June 2000.
  • Reports of IgD myeloma with testicular involvement are rare.
  • The histopathology of our patient's resected testis, i.e. the two myeloma cell-plasmacytoid and lymphoid cell components showing differential immunostaining, was unique.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Aged. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Immunoglobulin D / blood. Male. Neoplasm Invasiveness. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11808083.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin D; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; VAD protocol
  • [Number-of-references] 24
  •  go-up   go-down


14. Watanabe A, Matsukawa Y, Miyagi K, Kura Y, Yamazaki T, Sawada U, Sawada S, Horie T, Sugitani M, Nemoto N, Arakawa Y: Huge IgD plasmacytoma in the abdomen presenting coagulation necrosis. J Int Med Res; 2004 Sep-Oct;32(5):552-7
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge IgD plasmacytoma in the abdomen presenting coagulation necrosis.
  • A 65-year-old Japanese woman was diagnosed in 1996 with a pathological fracture of the left femur caused by immunoglobulin D-type myeloma (IgD myeloma).
  • She responded well to combination chemotherapy followed by irradiation.
  • In 1999, large plasmacytomas developed in the abdomen and left humerus.
  • We initiated irradiation therapy without chemotherapy to prevent further growth of the plasmacytoma, although treatment-resistant gastroduodenal ulcers developed.
  • We conclude that the use of combination chemotherapy with topical irradiation was an acceptable treatment measure against IgD plasmacytoma; irradiation without chemotherapy was the most likely cause of the coagulation necrosis seen in the plasmacytoma at autopsy.
  • [MeSH-major] Abdominal Neoplasms. Immunoglobulin D / metabolism. Multiple Myeloma / complications. Plasmacytoma
  • [MeSH-minor] Aged. Diagnosis, Differential. Fatal Outcome. Female. Femur / pathology. Humans. Japan. Necrosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15458289.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


15. Amine B, Benbouazza K, Harzy T, Rahmouni R, Guedira N, Lazrak N, Hajjaj-Hassouni N: IgD kappa myeloma: a new case. Joint Bone Spine; 2004 Jul;71(4):331-3
Hazardous Substances Data Bank. NOVANTRONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD kappa myeloma: a new case.
  • IgD myeloma, which is particularly severe, accounts for only 1-3% of all myeloma cases, and the kappa subtype contributes only 10-30% of IgD myelomas.
  • Immunoelectrophoresis, however, detected a faint IgD kappa band in the blood and a homogeneous kappa band in the urine.
  • Bone marrow aspirated from the sternum was found to contain 30% of malignant plasma cells.
  • Radiographs disclosed multiple punched-out lesions with no evidence of spinal cord compression.
  • Symptomatic treatment was given to correct the hypercalcemia, and combination chemotherapy was started.
  • DISCUSSION: IgD kappa myeloma is a severe variant of myeloma often associated with extraosseous lesions, renal failure, and amyloidosis.
  • The monoclonal component is absent or faint by serum protein electrophoresis, making the diagnosis difficult.
  • [MeSH-major] Immunoglobulin D. Immunoglobulin kappa-Chains. Multiple Myeloma / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Chlorambucil / administration & dosage. Humans. Hypercalcemia / etiology. Hypercalcemia / pathology. Male. Middle Aged. Mitoxantrone / administration & dosage. Prednisolone / administration & dosage. Renal Insufficiency / etiology. Renal Insufficiency / pathology. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15288860.001).
  • [ISSN] 1297-319X
  • [Journal-full-title] Joint, bone, spine : revue du rhumatisme
  • [ISO-abbreviation] Joint Bone Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin kappa-Chains; 18D0SL7309 / Chlorambucil; 9PHQ9Y1OLM / Prednisolone; BZ114NVM5P / Mitoxantrone; MCP protocol
  •  go-up   go-down


16. Li J, Zhao Y, Luo SK, Huang BH, Zhang GC, Peng AH, Zheng D, Su C, Xu DR, Tong XZ, Gu JL, Ding Y: [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma]. Zhonghua Yi Xue Za Zhi; 2008 Aug 5;88(30):2140-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical features, chemotherapy responses and survival of 223 patients with newly diagnosed multiple myeloma].
  • OBJECTIVE: To explore the proportion, clinical and laboratory features, chemotherapy responses and long term survival of different kinds of newly diagnosed multiple myeloma (MM) in China.
  • RESULTS: The proportions of each kind of MM including IgG, IgA, light chain, IgD, IgM and biclonal MM were 48.0%, 20.6%, 25.6%, 4.0%, 0.9% and 0.9% respectively.
  • No IgE and nonsecretory myeloma was found.
  • The median age of onset was 58 years, of which that of the IgA type was the oldest one and the light chain type was the youngest (P = 0.004).
  • The incidences of renal inadequacy, hypercalcemia and pathological fracture in light chain type were higher than those in IgG and IgA types.
  • The clinical features of IgD type were similar to that of the light-chain type.
  • The total chemotherapy efficacy rate of 89 patients who were treated with more than 3 cycles in our hospital is 61.8%, which has no difference in all types.
  • CONCLUSION: IgG is the most common type in MM.
  • Immunofixation electrophoresis should be performed routinely to avoid missed diagnosis of light-chain and IgD types of MM.
  • [MeSH-major] Multiple Myeloma / drug therapy. Multiple Myeloma / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunoglobulin Isotypes / immunology. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080477.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Immunoglobulin Isotypes
  •  go-up   go-down


17. Maisnar V, Hájek R, Scudla V, Gregora E, Büchler T, Tichý M, Kotoucek P, Kafková A, Forraiová L, Minarík J, Radocha J, Bláha V, Malý J: High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma. Bone Marrow Transplant; 2008 Jan;41(1):51-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy followed by autologous stem cell transplantation changes prognosis of IgD multiple myeloma.
  • Immunoglobulin D (IgD) multiple myeloma (MM) is a rare plasma cell disorder constituting less than 2% of all MM cases.
  • Survival of patients with IgD MM is generally shorter than that of patients with other types of monoclonal (M-) protein.
  • We have retrospectively analyzed patients with IgD MM participating in clinical trials of the Czech Myeloma Group.
  • Twenty-six IgD MM patients treated between 1996 and 2006 were identified, 14 (54%) men and 12 (46%) women.
  • Ten of 26 patients (39%) were treated with first-line high-dose chemotherapy (HDCT) using melphalan 200 mg/m(2) followed by autologous stem cell transplantation (ASCT).
  • Thirteen of 26 patients (50%) received conventional chemotherapy (CHT), mostly melphalan and prednisone or a vincristine/doxorubicin/dexamethasone (VAD) regimen.
  • Treatment responses were evaluable for 23 of 26 (89%) patients.
  • All HDCT patients had treatment responses, including seven patients (70%) with complete responses and three patients (30%) with partial responses.
  • In conclusion, the overall response rate for patients with IgD MM aged 65 years or less treated with HDCT and ASCT is similar to that seen in other MM types.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Immunoglobulin D. Multiple Myeloma / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Haematol. 2016;136(3):140-6 [27409804.001]
  • (PMID = 17934529.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


18. Iwasaki T, Hamano T, Ogata A, Hashimoto N, Kakishita E: IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement. Acta Haematol; 2000;104(1):42-5
MedlinePlus Health Information. consumer health - Multiple Myeloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IgD multiple myeloma preceding the development of extensive extramedullary disease without medullary involvement.
  • We present a unique case of IgD multiple myeloma (MM) preceding the development of extensive extramedullary disease without medullary involvement.
  • A 63-year-old man was diagnosed with IgD-lambda MM when he developed anemia.
  • After 3 months of chemotherapy, he was in complete remission as evidenced by the disappearance of bone marrow (BM) plasmacytosis, monoclonal IgD protein in his serum, and Bence Jones proteinuria.
  • Six months after diagnosis, his disease took an unusual course with the development of plasmacytomas in the skin, without medullary involvement.
  • He then received chemotherapy, resulting in the complete disappearance of the subcutaneous plasmacytomas.
  • Two years after the initial diagnosis, his disease took an aggressive clinical course with retroperitoneal relapse, leading to the patient's death within 1 month.
  • This case provides evidence of two separate transformations of the original malignant MM clone.
  • [MeSH-major] Immunoglobulin D / blood. Multiple Myeloma / immunology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cell Transformation, Neoplastic. Clone Cells / pathology. Humans. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Plasmacytoma / drug therapy. Plasmacytoma / enzymology. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Multiple myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11111122.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Immunoglobulin D; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


19. Kitamura K, Takeuchi J, Kanbe E, Oka H, Saiki M, Aikawa S, Kura Y, Hatta Y, Yamazaki T, Ito T, Sawada U, Horie T: [Multiple myeloma of the IgD-lambda type invading CNS]. Rinsho Ketsueki; 2004 Oct;45(10):1124-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple myeloma of the IgD-lambda type invading CNS].
  • She was found to have pancytopenia and high serum levels of LDH and IgD.
  • A bone marrow examination showed 63.8% of plasma cells and serum immunoelectrophoresis showed M-protein of the IgD-lambda type.
  • She was diagnosed as having multiple myeloma and transferred to our department.
  • VAD therapy was started from August 22.
  • Although the plasma cells in the bone marrow almost disappeared, the right lower abdominal mass remained and a new mass appeared on the right frontal chest wall after two courses of the treatment.
  • Combination chemotherapy with vincristine, ranimustine, melphalan, and dexamethasone (ROAD) was started on November 1.
  • This was followed with thalidomide and radiation therapy of the right inguinal region was added.
  • The plasma cells disappeared after the 6th intrathecal injection with MTX and prednisolone and the chemotherapy was resumed.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / therapy. Multiple Myeloma / pathology. Multiple Myeloma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers / analysis. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Fatal Outcome. Female. Humans. Immunoglobulin D / blood. Injections, Spinal. Interferon-alpha / administration & dosage. Melphalan / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Myeloma Proteins / analysis. Neoplasm Invasiveness. Nitrosourea Compounds / administration & dosage. Prednisolone / administration & dosage. Radiotherapy, Adjuvant. Thalidomide / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. THALIDOMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553049.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Immunoglobulin D; 0 / Interferon-alpha; 0 / Myeloma Proteins; 0 / Nitrosourea Compounds; 0 / multiple myeloma M-proteins; 4Z8R6ORS6L / Thalidomide; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 9PHQ9Y1OLM / Prednisolone; Q41OR9510P / Melphalan; YL5FZ2Y5U1 / Methotrexate; ROAD-IN protocol; VAD protocol
  •  go-up   go-down


20. Fukuno K, Tsurumi H, Yamada T, Oyama M, Moriwaki H: [Complete remission of plasmablastic IgD lambda multiple myeloma induced by continuous infusion of low-dose cytarabine and etoposide]. Rinsho Ketsueki; 2000 Jun;41(6):513-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of plasmablastic IgD lambda multiple myeloma induced by continuous infusion of low-dose cytarabine and etoposide].
  • Laboratory findings were as follows: hemoglobin level, 10.1 g/dl; platelet count, 1.8 x 10(4)/microliter; ALT, 56 IU/l; LDH, 3,570 IU/l; IgG, 653 mg/dl; IgA, 64 mg/dl; IgM, 49 mg/dl; IgD, 674 mg/dl.
  • Serum immunoelectrophoresis confirmed IgD lambda M-component.
  • Bone marrow aspiration showed 79.2% myeloma cells expressing a mostly plasmablastic morphology.
  • No plasmablastic myeloma cells were detected, but 2.1% mature plasma cells were found in his bone marrow on day 20.
  • On day 18 his platelet count exceeded 10.8 x 10(4)/microliter, and the serum IgD level fell to 210 mg/dl.
  • Therapy consisting of melphalan, methylprednisolone and vincristine was started from day 23.
  • No IgD lambda M-component was detectable by serum immunoelectrophoresis seven months after the diagnosis of multiple myeloma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Multiple Myeloma / drug therapy
  • [MeSH-minor] Aged. Cytarabine / administration & dosage. Etoposide / administration & dosage. Humans. Infusions, Intravenous. Male. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10921352.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide
  •  go-up   go-down


21. Schmielau J, Teschendorf C, König M, Schmiegel W, Graeven U: Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leuk Lymphoma; 2005 Apr;46(4):567-9
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma.
  • The use of the proteasome inhibitor bortezomib has been recently introduced into the treatment of relapsed, refractory multiple myeloma (MM).
  • We here demonstrate a case of a patient with IgD MM who was successfully treated with a combination of bortezomib, thalidomide, and dexamethasone.
  • Relapse of the disease occurred following tandem autologous transplantation and was refractory to a salvage therapy consisting of thalidomide, cyclophosphamide, etoposide, and dexamethasone.
  • While the administration of thalidomide was continued, the addition of bortezomib and dexamethasone led to a complete remission after 2 cycles of therapy.
  • The feasibility of this treatment is supported by a recently reported phase I/II trial that used a lower dose of thalidomide in combination with an equal dose of bortezomib.
  • This is the first report of a patient with IgD MM treated accordingly, suggesting that this entity is highly sensitive to the novel therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Boronic Acids / administration & dosage. Dexamethasone / administration & dosage. Immunoglobulin D / blood. Multiple Myeloma / drug therapy. Pyrazines / administration & dosage. Thalidomide / administration & dosage
  • [MeSH-minor] Bortezomib. Disease-Free Survival. Fatal Outcome. Humans. Male. Middle Aged. Recurrence. Remission Induction / methods. Salvage Therapy

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019485.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Immunoglobulin D; 0 / Pyrazines; 4Z8R6ORS6L / Thalidomide; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


22. Mochizuki K, Katayama K, Kikuchi F, Saito I, Homori M: Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor. Skeletal Radiol; 2001 Mar;30(3):166-9
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin D myeloma presenting as an extraosseous soft tissue tumor.
  • We report a 69-year-old man who suffered an extraosseous tumor of immunoglobulin D myeloma (lambda type) in the shoulder girdle, mimicking a primary soft tissue sarcoma.
  • Although the tumor showed a complete response to the initial chemotherapy, the patient died of the disease 31 months after its initial manifestation.
  • [MeSH-major] Multiple Myeloma / diagnosis. Shoulder. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Dacarbazine / therapeutic use. Doxorubicin / therapeutic use. Humans. Ifosfamide / therapeutic use. Immunoglobulin D. Immunoglobulin lambda-Chains. Magnetic Resonance Imaging. Male. Mesna / therapeutic use

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11357456.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin lambda-Chains; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


23. Fukai J, Nohgawa M, Uematsu Y, Itakura T, Kamei I: Immunoglobulin D multiple myeloma involving the sella manifesting as oculomotor palsy: case report. Neurosurgery; 2010 Aug;67(2):E505-6
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunoglobulin D multiple myeloma involving the sella manifesting as oculomotor palsy: case report.
  • OBJECTIVE: Immunoglobulin D multiple myeloma (IgD MM) is an uncommon type of MM characterized by an aggressive clinical behavior and a short survival time.
  • We report a rare case in which oculomotor palsy caused by a sellar lesion was the initial manifestation of IgD MM; systemic treatments were beneficial in this case.
  • At the time of admission, the patient had no symptoms of MM.
  • Appropriate laboratory studies, a bone scan, and a bone marrow biopsy led to a diagnosis of IgD lambda-type MM.
  • High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation was therapeutically beneficial.
  • CONCLUSION: This case demonstrates that an unusual sellar tumor might be the first manifestation of IgD MM.
  • Careful observation can suggest a possible non-pituitary etiology for a tumor, leading to appropriate diagnostic and therapeutic procedures.
  • [MeSH-major] Immunoglobulin D. Multiple Myeloma / therapy. Ophthalmoplegia / etiology. Pituitary Neoplasms / therapy. Sella Turcica / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Blood Protein Electrophoresis. Bone Marrow / pathology. Bone and Bones / pathology. Combined Modality Therapy. Cord Blood Stem Cell Transplantation. Cranial Nerve Diseases / etiology. Cranial Nerve Diseases / pathology. Diplopia / etiology. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasms, Plasma Cell / surgery. Neurosurgical Procedures. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20644379.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulin D
  •  go-up   go-down


24. Ikeda H, Hayashi T, Nojima M, Yasui H, Ikeda Y, Ishida T, Adachi M, Imai K: [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma]. Rinsho Ketsueki; 2005 Apr;46(4):269-73
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
  • We describe 2 cases of conventional therapy-resistant multiple myeloma (MM) that responded to bortezomib and dexamethasone therapy.
  • Case 1: A 62-year-old woman with MM (IgG, kappa-type, stage IIIA) resistant to DMVM-IFN (dexamethasone, ranimustine, vincristine, melphalan, interferon-a), VAD (vincristine, doxorubicin, dexamethasone), high-dose melphalan with autologous peripheral blood stem cell transplantation (PBSCT) and thalidomide, received 2 courses of bortezomib treatment.
  • The patient's serum IgG level decreased from 8040 to 1020 mg/dl and the level of plasma cells in bone marrow was 1.2% after the treatments.
  • Case 2: A 43-year-old man with MM (IgD, gamma-type, stage IIA) resistant to conventional and high-dose chemotherapy with PBSCT as well as thalidomide therapy, received treatment with bortezomib alone and then in combination with dexamethasone.
  • His serum IgD level decreased from 2140 to 623 mg/dl.
  • These results indicate that the combination of bortezomib and dexamethasone is effective in the treatment of refractory MM and that dexamethasone can reduce the adverse reactions of bortezomib.
  • [MeSH-major] Anti-Inflammatory Agents / administration & dosage. Antineoplastic Agents / administration & dosage. Boronic Acids / administration & dosage. Dexamethasone / administration & dosage. Multiple Myeloma / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Bortezomib. Drug Administration Schedule. Drug Resistance, Neoplasm. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444959.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


25. Lora-Tamayo J, Palom X, Sarrá J, Gasch O, Isern V, Fernández de Sevilla A, Pujol R: Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases. Clin Lymphoma Myeloma; 2008 Dec;8(6):363-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple myeloma and hyperammonemic encephalopathy: review of 27 cases.
  • Hyperammonemic encephalopathy is a rarely reported complication of multiple myeloma (MM).
  • We describe an illustrative case of hyperammonemia in the setting of an immunoglobulin (Ig) D-lambda MM, and perform a systematic review of the English-written literature.
  • Most were IgA type (10 cases), and there were 2 cases of IgD type.
  • Most cases were aggressive or chemotherapy-resistant forms of MM.
  • Eight patients were diagnosed with MM at the same time as the episode of hyperammonemia.
  • Two patients did not receive chemotherapy and died.
  • Twenty-two out of 25 patients who received chemotherapy against MM showed a decrease in ammonium blood concentration, and of those, 15 survived the episode (68%).
  • In conclusion, hyperammonemia is a severe complication of MM, associated with a high mortality.
  • Chemotherapy directed against MM seems to be the most effective measure in order to achieve normal ammonium levels and clinical improvement.
  • [MeSH-major] Hyperammonemia / complications. Multiple Myeloma / complications. Neurotoxicity Syndromes / complications

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19064403.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 24
  •  go-up   go-down


26. Hayden PJ, O'Driscoll A, Gardiner N, Swords R, Sargent J, Ni Ainle F, Fortune A, Murphy PT, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty GM, Enright H, Conneally E, Vandenberghe E, McCann SR, Browne PV: Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003. Ir J Med Sci; 2005 Apr-Jun;174(2):26-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003.
  • BACKGROUND: High-dose treatment with autologous stem cell transplantation (ASCT) has become the standard of care for patients with myeloma below the age of 65 years.
  • RESULTS: Thirty-six patients had IgG, 11 IgA, 1 IgD, 9 light chain and 3 non-secretory MM.
  • Fifty-seven (95%) patients received anthracycline-corticosteroid combination chemotherapy prior to autografting.
  • CONCLUSION: Centre outcome is comparable to published international series and supports the use of ASCT in the treatment of this malignancy.
  • [MeSH-major] Multiple Myeloma / surgery. Peripheral Blood Stem Cell Transplantation. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3771-9 [11533101.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1447-56 [8622058.001]
  • [Cites] Lancet. 1983 Oct 8;2(8354):822-4 [6137651.001]
  • [Cites] Br J Haematol. 2001 Sep;114(3):600-7 [11552985.001]
  • [Cites] Bone Marrow Transplant. 2004 Apr;33(8):823-8 [14767499.001]
  • [Cites] Blood. 2000 Jan 1;95(1):7-11 [10607678.001]
  • [Cites] Blood. 1995 Jan 15;85(2):588-96 [7529066.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):822-9 [11564069.001]
  • [Cites] N Engl J Med. 2003 May 8;348(19):1875-83 [12736280.001]
  • [Cites] Bone Marrow Transplant. 2004 Mar;33(6):623-8 [14730336.001]
  • [Cites] Br J Haematol. 2001 Dec;115(3):522-40 [11736932.001]
  • [Cites] N Engl J Med. 1999 Nov 18;341(21):1565-71 [10564685.001]
  • [Cites] Blood. 2004 Jan 1;103(1):20-32 [12969978.001]
  • [Cites] Cancer. 2003 Oct 15;98(8):1735-44 [14534891.001]
  • [Cites] Bone Marrow Transplant. 2004 Jan;33(1):61-4 [14704657.001]
  • [Cites] Blood. 1999 Jan 1;93(1):55-65 [9864146.001]
  • [Cites] Biomed Pharmacother. 2002 Jul;56(5):223-34 [12199621.001]
  • [Cites] Hematol J. 2004;5(1):9-23 [14745425.001]
  • [Cites] J Clin Oncol. 1998 Dec;16(12):3832-42 [9850028.001]
  • [Cites] Br J Cancer. 1980 Dec;42(6):813-22 [7006663.001]
  • [Cites] Bone Marrow Transplant. 2004 Jul;34(2):161-7 [15133489.001]
  • [Cites] Haematologica. 2002 Jun;87(6):609-14 [12031917.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1858-68 [10068658.001]
  • [Cites] Br J Haematol. 1996 Jun;93(4):931-4 [8703828.001]
  • [Cites] Bone Marrow Transplant. 2003 Feb;31(3):163-70 [12621476.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:419-37 [14633793.001]
  • [Cites] N Engl J Med. 1996 Jul 11;335(2):91-7 [8649495.001]
  • [Cites] Hematol J. 2003;4(6):379-98 [14671610.001]
  • [Cites] Blood. 2002 Feb 1;99(3):731-5 [11806971.001]
  • [Cites] Br J Haematol. 1998 Sep;102(5):1115-23 [9753033.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3469-70 [12893762.001]
  • [Cites] Blood. 1986 May;67(5):1298-301 [3516252.001]
  • [Cites] Am J Hematol. 1990 Feb;33(2):86-9 [2301376.001]
  • (PMID = 16094909.001).
  • [ISSN] 0021-1265
  • [Journal-full-title] Irish journal of medical science
  • [ISO-abbreviation] Ir J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


27. Maachi M, Fellahi S, Diop ME, Francois T, Capeau J, Bastard JP: [Pleural effusion as a first sign of Ig D lambda multiple myeloma]. Ann Med Interne (Paris); 2003 Feb;154(1):70-2
Hazardous Substances Data Bank. PREDNISONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural effusion as a first sign of Ig D lambda multiple myeloma].
  • Immunoglobulin D (IgD) multiple myeloma is rare, accounting for less than 2% of all patients with multiple myeloma.
  • We report a case of Ig D lambda multiple myeloma in a 74-year-old man that was revealed by pleural effusion and dyspnea.
  • This effusion was found to be caused by multiple myeloma after electrophoretic and cytologic assays.
  • The patient received a course of chemotherapy with melphalan and prednisone.
  • Pleural effusion as a first sign of Ig D multiple myeloma is rarely described and the prognosis associated with such a localisation is very poor.
  • [MeSH-major] Immunoglobulin D / analysis. Immunoglobulin lambda-Chains / analysis. Multiple Myeloma / diagnosis. Pleural Effusion / etiology
  • [MeSH-minor] Aged. Anti-Inflammatory Agents / administration & dosage. Anti-Inflammatory Agents / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Drug Therapy, Combination. Dyspnea / etiology. Humans. Immunoelectrophoresis. Male. Melphalan / administration & dosage. Melphalan / therapeutic use. Prednisone / administration & dosage. Prednisone / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12746663.001).
  • [ISSN] 0003-410X
  • [Journal-full-title] Annales de médecine interne
  • [ISO-abbreviation] Ann Med Interne (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Immunoglobulin D; 0 / Immunoglobulin lambda-Chains; Q41OR9510P / Melphalan; VB0R961HZT / Prednisone
  •  go-up   go-down


28. Hanf W, Guillaume C, Jolivot A, Chapuis-Cellier C, Guebre-Egziabher F, Fontana A, Fouque D, Juillard L: Prolonged hemodialysis for acute kidney injury in myeloma patients. Clin Nephrol; 2010 Oct;74(4):319-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged hemodialysis for acute kidney injury in myeloma patients.
  • OBJECTIVE: Cast nephropathy, due to free light chain (FLC) toxicity, is the main cause of acute kidney injury in multiple myeloma, with about 10% of patients requiring dialysis.
  • In these patients, in addition to chemotherapy that prevents FLC production, daily hemodialysis using high cutoff or adsorptive membranes, showed promising results by decreasing quickly toxic serum FLC concentrations.
  • CASE HISTORY: We report here the case of 2 patients presenting with acute kidney injury and high FLC serum concentration and M-components one with IgG Kappa and the other with IgD lambda.
  • CONCLUSION: Despite similar range of depuration, serum plasma FLC decreased importantly in the patient with the kappa type who recovered but was unchanged in the lambda type patient who remained under maintenance dialysis.
  • Further studies are needed to confirm this new approach therapy.
  • [MeSH-major] Acute Kidney Injury / therapy. Multiple Myeloma / complications. Renal Dialysis
  • [MeSH-minor] Aged. Female. Humans. Immunoglobulin Light Chains / blood. Immunoglobulin Light Chains / toxicity. Male

  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20875387.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin Light Chains
  •  go-up   go-down


29. Patriarca F, Gaidano G, Capello D, Zaja F, Fanin R, Baccarani M: Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation. Haematologica; 2000 Sep;85(9):982-5
Hazardous Substances Data Bank. VIDARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occurrence of multiple myeloma after fludarabine treatment of a chronic lymphocytic leukemia: evidence of a biclonal derivation and clinical response to autologous stem cell transplantation.
  • BACKGROUND AND OBJECTIVES: The occurrence of chronic lymphocyte leukemia (CLL) and multiple myeloma (MM) in a single individual is rare and there is no consensus about the clonal relationship of the two disorders and no clinical data about the response to therapy.
  • DESIGN AND METHODS: We describe a 49-year old patient who developed a III stage IgD k MM after fludarabine treatment for a previous diagnosis of CLL and then was submitted to an high-dose treatment with autologous CD34+ selected stem cell support.
  • An immunologic and molecular characterisation of peripheral blood and bone marrow was performed at the time of appearance of the two coexisting neoplasms.
  • RESULTS: By immunophenotyping, monoclonal B-lymphocytes stained with l chains, whereas marrow plasma cells were positive for k chains.
  • During an 18 months follow-up after autotransplantation, the CLL-related clone became undetectable, whereas MM persisted with a minimal amount of Bence Jones proteinuria and a 15-20% plasma cell marrow infiltration.
  • [MeSH-major] Multiple Myeloma / etiology. Vidarabine / analogs & derivatives
  • [MeSH-minor] Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. B-Lymphocytes / immunology. Clone Cells / immunology. Clone Cells / pathology. Gene Rearrangement. Hematopoietic Stem Cell Transplantation. Humans. Immunoglobulin Heavy Chains. Immunophenotyping. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / immunology. Male. Middle Aged. Neoplasms, Second Primary / etiology. Neoplasms, Second Primary / immunology. Transplantation, Autologous


30. Michopoulos S, Petraki K, Petraki C, Dimopoulos MA: Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome. Dig Dis Sci; 2002 Apr;47(4):730-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Light chain deposition disease of the liver without renal involvement in a patient with multiple myeloma related to liver failure and rapid fatal outcome.
  • We describe a 36-year-old man with advanced multiple myeloma (Salmon and Durie stage III) who developed jaundice and severe cholestasis after a first cure with systemic chemotherapy of vincristine, doxorubicin, and oral dexamethasone (VAD).
  • Immunohistochemistry showed positivity for kappa-light chains and was negative for lambda-light chains, for IgA, IgG, IgM, and IgD immunoglobulins as well as for AA and AL proteins and for amyloid P component.
  • A diagnosis of light chain deposition disease (LCDD) of the liver was made.
  • The patient developed rapid deterioration of liver function, leading to a multisystem dysfunction and death.
  • The occurrence of LCDD in multiple myeloma is close to 5% and myeloma is the underlying disease in two thirds of patients with LCDD.
  • This is the first observation of LCDD presenting with jaundice and severe cholestasis shortly after the diagnosis of high tumor mass myeloma, without overt renal involvement, leading rapidly to the patient's death.
  • [MeSH-major] Immunoglobulin Light Chains / metabolism. Liver Diseases / complications. Liver Diseases / metabolism. Liver Failure / etiology. Multiple Myeloma / complications
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Liver / metabolism. Liver / pathology. Male. Time Factors


31. Matsue K, Fujiwara H, Iwama K, Kimura S, Yamakura M, Takeuchi M: Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years. Ann Hematol; 2010 Mar;89(3):291-7
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reversal of dialysis-dependent renal failure in patients with advanced multiple myeloma: single institutional experiences over 8 years.
  • Acute renal failure in patients with multiple myeloma (MM) requiring dialysis is a serious complication and is associated with extremely poor survival.
  • In addition, its treatment included high-dose dexamethasone and/or thalidomide-containing regimens on the reversibility of renal function, which has not been adequately evaluated previously.
  • There were seven light chain only myelomas, three IgD myelomas, and two IgG myelomas.
  • Ten patients initially received high-dose dexamethasone-based treatment and two received thalidomide-based treatment, with modifications.
  • Dialysis independency was achieved in all eight patients (67%) who achieved better than PR, with a median duration of 2.0 months.
  • A high concentration of serum-free light chain was detected in all patients examined, before the start of anti-myeloma treatment, and this was associated with the presence of advanced renal failure.
  • These results suggest that dialysis-dependent renal failure is reversible by dexamethasone- or thalidomide-based treatments in most patients with MM, even if the patient is in advanced age, and that serum-free light chain monitoring might be useful for predicting improvements in renal function.
  • [MeSH-major] Multiple Myeloma / complications. Multiple Myeloma / drug therapy. Renal Dialysis. Renal Insufficiency / drug therapy. Renal Insufficiency / etiology
  • [MeSH-minor] Aged. Aged, 80 and over. Dexamethasone / pharmacology. Dexamethasone / therapeutic use. Humans. Immunoglobulin D. Immunoglobulin G. Immunosuppressive Agents / therapeutic use. Middle Aged. Remission Induction. Retrospective Studies. Thalidomide / pharmacology. Thalidomide / therapeutic use. Treatment Outcome

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Hematol. 2010 Jun;89(6):627-8 [19784650.001]
  • (PMID = 19693498.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


32. Hayashi T, Yamaguchi I, Saitoh H, Takagi M, Nonaka Y, Nomura T: Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis. Intern Med; 2003 Jul;42(7):605-8
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide treatment for immunoglobulin D multiple myeloma in a patient on chronic hemodialysis.
  • A 64-year-old Japanese man suffering from IgD lambda myeloma and renal failure requiring chronic hemodialysis was treated with thalidomide.
  • Serum IgD concentration was 4,050 mg/dl and myeloma cells constituted 95.6% of nucleated cells in bone marrow at the start of treatment.
  • Thalidomide caused peripheral neuropathy and constipation at a dose of 100 mg daily in the first week of treatment, but adverse effects resolved upon dose reduction.
  • Thalidomide represents a valid therapeutic option for some myeloma patients receiving hemodialysis.
  • [MeSH-major] Immunoglobulin D / blood. Immunosuppressive Agents / therapeutic use. Multiple Myeloma / drug therapy. Renal Dialysis. Thalidomide / therapeutic use
  • [MeSH-minor] Humans. Kidney Failure, Chronic / complications. Kidney Failure, Chronic / therapy. Male. Middle Aged

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Dialysis.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Intern Med. 2003 Jul;42(7):550-1 [12879943.001]
  • [CommentIn] Nephrol Dial Transplant. 2005 Sep;20(9):2011-2 [16046513.001]
  • (PMID = 12879955.001).
  • [ISSN] 0918-2918
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Immunoglobulin D; 0 / Immunosuppressive Agents; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


33. Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A: Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant; 2003 Feb;31(3):163-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
  • High-dose therapy with autologous stem cell transplantation (ASCT) has become the treatment of choice for symptomatic eligible patients with multiple myeloma (MM).
  • In all, 69 patients had IgG, 28 IgA, 23 light chain, one IgD and six non secretory MM.
  • At the time of autograft, 6% of patients were in complete remission (CR), 73% in partial remission (PR), 12% showed minor response to previous treatment and 9% had stable or refractory disease.
  • Prior to autograft, 79% of cases had received only one line of chemotherapy and 21% two or more lines.
  • We evaluated the influence of age (using as cutoff value the ages of 55, 60 and 65 years), type of MM, status pre- and post-ASCT, number of lines of previous regimens, time of ASCT from diagnosis, year of autograft, dose of reinfused CD34+ cells, plasma cell infiltration and beta(2)-microglobulin at diagnosis on overall (OS) and progression-free survivals (PFS) to define patients with better prognosis.
  • Median OS from diagnosis was 79.7 months.
  • We conclude that ASCT is a safe and effective procedure even in resistant cases.
  • The outcome was independent of age, time from diagnosis, previous treatment and conditioning regimen, but there was a tendency for better survival in the nonsecretory patients.
  • [MeSH-major] Multiple Myeloma / therapy. Stem Cell Transplantation / methods. Transplantation Conditioning / methods
  • [MeSH-minor] Age Factors. Aged. Female. Follow-Up Studies. Humans. Immunoglobulin A / blood. Immunoglobulin D / blood. Immunoglobulin G / blood. Immunoglobulin Light Chains / blood. Male. Melphalan / therapeutic use. Middle Aged. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Autologous. Treatment Outcome. Whole-Body Irradiation

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12621476.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunoglobulin A; 0 / Immunoglobulin D; 0 / Immunoglobulin G; 0 / Immunoglobulin Light Chains; Q41OR9510P / Melphalan
  •  go-up   go-down


34. Minauchi K, Fujie T, Matsubara N, Kasahara H, Ogura Y, Tamura M, Yamane Y, Tanaka M, Taneichi K: [Primary plasma cell leukemia (IgD-lambda) with hyperammonemia]. Nihon Naika Gakkai Zasshi; 2004 Jan 10;93(1):139-41
Hazardous Substances Data Bank. Ammonia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary plasma cell leukemia (IgD-lambda) with hyperammonemia].
  • [MeSH-minor] Ammonia / blood. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Humans. Immunoglobulin D / analysis. Middle Aged. Multiple Myeloma / complications. Multiple Myeloma / diagnosis. Multiple Myeloma / drug therapy. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hyperammonemia.
  • Genetic Alliance. consumer health - Plasma cell leukemia.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14968586.001).
  • [ISSN] 0021-5384
  • [Journal-full-title] Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine
  • [ISO-abbreviation] Nippon Naika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin D; 5J49Q6B70F / Vincristine; 7664-41-7 / Ammonia; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol; VAD protocol
  •  go-up   go-down






Advertisement